Patents by Inventor Marian Gorecki

Marian Gorecki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8540983
    Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: September 24, 2013
    Assignee: MediWound Ltd.
    Inventors: Marian Gorecki, Amir Toren
  • Publication number: 20120171187
    Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.
    Type: Application
    Filed: February 6, 2012
    Publication date: July 5, 2012
    Inventors: Marian Gorecki, Amir Toren
  • Patent number: 8119124
    Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: February 21, 2012
    Assignee: MediWound Ltd.
    Inventors: Marian Gorecki, Amir Toren
  • Publication number: 20090148429
    Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.
    Type: Application
    Filed: November 22, 2005
    Publication date: June 11, 2009
    Inventors: Marian Gorecki, Amir Toren
  • Publication number: 20090010910
    Abstract: The invention relates to compositions for debriding damaged skin comprising at least one enzymatic debriding agent and at least one antiseptic compound comprising heavy metal ions. The present invention further relates to kit and methods for topical debridement of damaged skin, particularly of burned skin.
    Type: Application
    Filed: July 13, 2005
    Publication date: January 8, 2009
    Applicant: MEDIWOUND LTD.
    Inventors: Amir Toren, Lior Rosenberg, Marian Gorecki
  • Patent number: 6229003
    Abstract: The present invention relates to strains of E coli adapted to produce bovine growth hormone, being the result of extraction of RNA from bovine pituitaries, transcription of DNA on such RNA templates, splicing of DNA into plasmids, insertion of spliced plasmid into microorganisms, and further subjecting the microorganisms to selection and isolating the colonies producing the desired fused or modified growth hormone and to modified bovine growth hormone obtained by the cultivation of such modified E. coli strains and recovery of the desired product.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 8, 2001
    Assignee: Yeda Research and Development Company Ltd.
    Inventors: Haim Aviv, Eliyahu Keshet, Marian Gorecki, Arie Rosner
  • Patent number: 6054291
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: April 25, 2000
    Assignee: Bio-Technology General Corp.
    Inventors: Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel
  • Patent number: 6030611
    Abstract: Improved methods for production of recombinant human superoxide dismutase and analogs thereof have been developed. Such superoxide dismutase or analogs may be used to catalyze the reduction of superoxide radicals thereby preventing or treating injury resulting from the presence of such superoxide radicals.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: February 29, 2000
    Assignee: Bio-Technology General Corp.
    Inventors: Marian Gorecki, Amnon Gonenne
  • Patent number: 6001604
    Abstract: An improved and efficient process for the production of recombinant human insulin by folding of a proinsulin hybrid polypeptide is provided.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: December 14, 1999
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Simona Mendelovitz, Marian Gorecki
  • Patent number: 5948668
    Abstract: The subject invention provides a method of producing enzymatically active CPB which comprises treating a recombinant cell containing DNA encoding ProCPB, so that the DNA directs expression of the ProCPB, recovering from the cell the ProCPB so expressed, treating the recovered ProCPB under conditions permitting folding of the ProCPB, subjecting the folded ProCPB to enzymatic cleavage to produce enzymatically active CPB and purifying the enzymatically active CPB.
    Type: Grant
    Filed: January 13, 1997
    Date of Patent: September 7, 1999
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob Hartman, Netta Fulga, Simona Mendelovitch, Marian Gorecki
  • Patent number: 5759816
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 2, 1998
    Assignee: Bio-Technology General Corp.
    Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Giladi, Marian Gorecki, Tikva Vogel
  • Patent number: 5670371
    Abstract: A plasmid for the production of superoxide dismutase or an analog thereof which upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of DNA encoding superoxide dismutase and production of superoxide dismutase. The plasmid is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: September 23, 1997
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Jacob Hartman
  • Patent number: 5637495
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: June 10, 1997
    Assignee: Bio-Technology General Corp.
    Inventors: Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel
  • Patent number: 5527691
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.
    Type: Grant
    Filed: June 28, 1994
    Date of Patent: June 18, 1996
    Assignee: Bio-Technology General Corp.
    Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Galadi, Marian Gorecki, Tikva Vogil
  • Patent number: 5457042
    Abstract: A novel analog of human superoxide dismutase which comprises the non-acetylated, non-glycosylated form of natural human superoxide dismutase having the ser-met amino acid sequence attached to the N-terminus and a mixture comprising this analog and non-acetylated, non-glycosylated superoxide dismutase having an amino acid sequence identical to that of natural human superoxide dismutase are provided. Methods of catalyzing a chemical reaction using the novel analog and mixture are provided.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: October 10, 1995
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Amos B. Oppenheim, Marian Gorecki, Haim Aviv, Rachel Oren
  • Patent number: 5455029
    Abstract: An improved plasmid for the production of superoxide dismutase on an analog thereof which upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a gene encoding superoxide dismutase or the analog. The plasmid is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon; a second restriction enzyme site; a gene encoding superoxide dismutase or the analog; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the plasmid is present in the host. The distance between the 3' end of P.sub.L O.sub.L and the 5' end of the N utilization site is less than about 80 base pairs.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: October 3, 1995
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Amos B. Oppenheim, Marian Gorecki, Haim Aviv, Rachel Oren
  • Patent number: 5256546
    Abstract: A plasmid for the production of porcine growth hormone or an analog thereof which upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of DNA encoding porcine growth hormone and production of porcine growth hormone or analogs thereof.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: October 26, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 5198361
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: January 3, 1991
    Date of Patent: March 30, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 5162217
    Abstract: An improved plasmid for the production of superoxide dismutase which upon introduction into a host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a gene encoding superoxide dismutase. The plasmid which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon; a second restriction enzyme site; a gene encoding superoxide dismutase; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the plasmid is present in the host. The distance between the 3' end of P.sub.L O.sub.L and the 5' end of the N utilization site is less than about 80 base pairs.
    Type: Grant
    Filed: December 8, 1989
    Date of Patent: November 10, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Amos B. Oppenheim, Marian Gorecki, Haim Aviv, Rachel Oren
  • Patent number: 5143836
    Abstract: An improved plasmid for the production of superoxide dismutase which upon introduction into a host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a gene encoding superoxide dismutase. The plasmid includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon; a second restriction enzyme site; a gene encoding superoxide dismutase; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the plasmid is present in the host. The distance between the 3' end of P.sub.L O.sub.L and the 5' end of the N utilization site is less than about 80 base pairs.
    Type: Grant
    Filed: May 13, 1988
    Date of Patent: September 1, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Amos B. Oppenheim, Marian Gorecki, Haim Aviv